Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD Study of HU6 in High BMI Volunteers
NCT04709913Phase 1Completed
- Sponsor
- Rivus Pharmaceuticals, Inc.
- Start
- Jan 2021
- Primary completion
- Apr 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) and obesity comparing HU6 with Placebo (2 arms). Primary endpoint: Maximum Plasma Concentration at 4 months. Started Jan 2021; status: completed.
02
Drugs
HU6
03
Conditions
Nonalcoholic steatohepatitis (NASH)obesity
Beyond the preview
Go deeper on NCT04709913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04709913.